{
  "dataset": "Strategic Signal — Corporate AI Data Transactions",
  "dataset_version": "1.0.11",
  "methodology_version": "1.0.0",
  "released_on": "2026-09-29",
  "observation_count": 14,
  "approved_record_count": 9,
  "change_type": "reviewed_addition",
  "previous_version": "1.0.10",
  "changes": [
    "SS-AIDT-2026-0012: Mike Ye approved the Tempus AI → Recursion Pharmaceuticals canonical AI Access data-rights arrangement. Tempus's proprietary de-identified clinical and molecular oncology corpus is licensed for explicit AI/ML training, improvement, modification and derivative-model work. The September 2026 amendment extends the same arrangement to six years, removes convenience termination, reduces the aggregate unique-record cap and resets the remaining third-through-fifth anniversary fees to $14 million each. Human Response is not established; this is not a second event."
  ],
  "known_limits": [
    "Only human_reviewed records count as approved observations.",
    "Bundled commitments and pending bids are not dataset purchase prices."
  ]
}